Although B cell depletion is an effective strategy for treating MuSK MG, relapse is common, as B cells, which produce antibodies that bind the first Ig-like domain in MuSK, persist and reemerge to disrupt MuSK function (38). The gene discussed is MUSK; the disease is myasthenia gravis.